82 related articles for article (PubMed ID: 17192511)
1. Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.
He YL; Horowitz A; Watson CE; Foley JE; Sallas W; Ligueros-Saylan M
J Clin Pharmacol; 2007 Jan; 47(1):127-31. PubMed ID: 17192511
[No Abstract] [Full Text] [Related]
2. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
He YL; Wang Y; Bullock JM; Deacon CF; Holst JJ; Dunning BE; Ligueros-Saylan M; Foley JE
J Clin Pharmacol; 2007 May; 47(5):633-41. PubMed ID: 17442688
[TBL] [Abstract][Full Text] [Related]
3. The role of vildagliptin in the management of type 2 diabetes mellitus.
Kleppinger EL; Helms K
Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
[TBL] [Abstract][Full Text] [Related]
4. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
5. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
6. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Foley JE; Ligueros-Saylan M; He YL; Holst JJ; Deacon CF; Dunning BE; Leone-Jones A; Yu T; Kelley DE
Horm Metab Res; 2008 Oct; 40(10):727-30. PubMed ID: 18597213
[No Abstract] [Full Text] [Related]
7. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
[TBL] [Abstract][Full Text] [Related]
8. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A
Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
[TBL] [Abstract][Full Text] [Related]
9. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
10. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Bosi E; Camisasca RP; Collober C; Rochotte E; Garber AJ
Diabetes Care; 2007 Apr; 30(4):890-5. PubMed ID: 17277036
[TBL] [Abstract][Full Text] [Related]
11. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
12. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Pei Z
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
J Pharm Belg; 2009 Jun; (2):64-6. PubMed ID: 19739530
[No Abstract] [Full Text] [Related]
14. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
15. The scientific evidence: vildagliptin and the benefits of islet enhancement.
Mathieu C
Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Del Prato S
Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Ahrén B
Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
[No Abstract] [Full Text] [Related]
19. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
Ahrén B; Foley JE
Int J Clin Pract Suppl; 2008 Mar; (159):8-14. PubMed ID: 18269436
[TBL] [Abstract][Full Text] [Related]
20. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
Panina G
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]